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Abstract
Objectives: To investigate the correlations between functional imaging markers derived from positron emission
tomography/computed tomography (PET/CT) and diffusion-weighted magnetic resonance imaging (DWI) in diffuse large
B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Further to compare the usefulness of these tumor markers in
differentiating diagnosis of the two common types of Non-Hodgkin’s lymphoma (NHL).
Materials and Methods: Thirty-four consecutive pre-therapy adult patients with proven NHL (23 DLBCL and 11 FL)
underwent PET/CT and MRI examinations and laboratory tests. The maximum standardized uptake value (SUVmax),
metabolic tumor volume (MTV), and metabolic tumor burden (MTB) were determined from the PET/CT images. DWI was
performed in addition to conventional MRI sequences using two b values (0 and 800 s/mm2). The minimum and mean
apparent diffusion coefficient (ADCmin and ADCmean) were measured on the parametric ADC maps.
Results: The SUVmax correlated inversely with the ADCmin (r =20.35, p,0.05). The ADCmin, ADCmean, serum thymidine kinase
(TK), Beta 2-microglobulin (B2m), lactate dehydrogenase (LD), and C-reactive protein (CRP) correlated with both whole-body
MTV and whole-body MTB (p,0.05 or 0.01). The SUVmax, TK, LD, and CRP were significantly higher in the DLBCL group than
in the FL group. Receiver operating characteristic curve analysis showed that they were reasonable predictors in
differentiating DLBCL from FL.
Conclusions: The functional imaging markers determined from PET/CT and DWI are associated, and the SUVmax is superior
to the ADCmin in differentiating DLBCL from FL. All the measured serum markers are associated with functional imaging
markers. Serum LD, TK, and CRP are useful in differentiating DLBCL from FL.
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Introduction
Non-Hodgkin’s lymphoma (NHL) represents a heterogeneous
group of lymphoid malignancies that display varying patterns of
biological behavior and response to treatment [1]. Prognosis of
patients with NHL is affected by the stage, grade, and histological
subtype. The most common subtypes of NHL affecting adults are
diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma
(FL), which together account for more than 50% of the incidences
of the disease [2]. Prognostic tumor markers may help to identify
high-risk patients who might benefit from more aggressive therapy.
Positron emission tomography/computed tomography (PET/CT)
with the use of 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) is an
established imaging modality that has been proven to be of benefit
in the management of malignant lymphomas [3]. Among the PET
parameters, standardized uptake value (SUV) is currently the most
commonly used semi-quantitative index of 18F-FDG metabolic
rate. SUV reflects tumor glucose metabolism, and is commonly
represented by the mean (SUVmean) or maximum (SUVmax) value.
In PET image analysis, SUVmax has the advantage of being
relatively operator independent. However, the measurement of
SUVmax has been confined to detection of the most obvious
metabolic activities of the tumor at a single site, but not the overall
tumor activity. SUVmean is the average value generated from the
entire tumor, but differences in operator contouring of tumor will
yield varying values. In addition, both SUVmax and SUVmean
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represent only the metabolic activity per gram of tissue, but they
are not able to reflect tumor dimensions and volume. In contrast,
metabolic tumor burden (MTB) (i.e., total lesion glycolysis) is a
newly proposed tumor marker in which both tumor activity and
volume are integrated. MTB is the product of SUVmean and
metabolic tumor volume (MTV). Lymphoma patients can have
single or multiple lesions depending on the stage of the disease. In
order to take the number of lesion into consideration, SUVsum
(summation of SUVmax for all tumors), whole-body MTV
(MTVwb; summation of MTV for all tumors) and whole-body
MTB (MTBwb; summation of MTB for all tumors) were calculated
in the present study and used as indexes that could potentially
reflect overall tumor activity or malignant process of the entire
body [4].
Cancer is not only characterized by pathological metabolism,
but also by the higher cellularity and morphological changes of
tumor cell and tissue [5]. Therefore, restricted water diffusion has
been found to be a common feature of tumors. Recent studies
have shown that diffusion-weighted magnetic resonance imaging
(DWI) is a valuable imaging modality for detecting metastasis and
cancer relapse [6]. DWI with apparent diffusion coefficient (ADC)
mapping provides information on tumor tissue aggressiveness.
ADC value has been applied to distinguish benign from malignant
lymph nodes [7,8], and it has also been used to assess treatment
response in various malignancies including lymphoma [6,9].
Tumors in NHL are typically heterogeneous and can have
different histological grades or subtypes in different tumors of the
same patient or even in a single tumor [8,10]. Various components
may influence the mean ADC (ADCmean) of the tumor/tumors. In
contrast, the minimum ADC (ADCmin) is the most malignant site
within the heterogeneous tumor/tumors [11]. In order to compare
the diagnostic significance of DWI, both ADCmin and ADCmean
were measured in the present study.
Both PET/CT and DWI are established imaging modalities in
tumor assessment including tumor aggressiveness, treatment
response, and prognosis, but they measure different aspects of
tumor pathophysiology. A few studies have recently compared
FDG-PET/CT and DWI in patients with different cancers, and
an inverse correlation between SUVmax and ADCmin has been
revealed [12–16]. There are also several well-known prognostic
clinical and laboratory predictors for newly diagnosed malignant
lymphoma, such as International Prognostic Index (IPI), Follicular
Lymphoma IPI (FLIPI), and elevated levels of serum thymidine
kinase (TK), Beta 2-microglobulin (B2m), lactate dehydrogenase
(LD) and C-reactive protein (CRP). The aim of this study was to
investigate the relationships between functional imaging markers
derived from PET/CT and DWI, as well as serum tumor markers
in DLBCL and FL. In addition, the study was desired to compare
the usefulness of these tumor markers in differentiating diagnosis
of the two common types of aggressive and indolent NHL.
Materials and Methods
Patients
Patients were enrolled from our prospective study investigating
the potential of PET/CT and MRI for early chemotherapy
response evaluation in patients with NHL. The inclusion criteria
were: at least 18 years old, histologically proven DLBCL or FL,
WHO performance scale (Zubrod score) better than 4. The
exclusion criteria were: concomitant previous malignant disease,
primary central nervous system lymphoma, pregnancy or lacta-
tion, psychosis, diabetes, human immunodeficiency virus infection
or acquired immunodeficiency syndrome, or other serious medical
conditions that would prevent imaging examination. The study
was approved by the Ethics Committee of Tampere University
Hospital, and all patients gave written informed consent prior to
study entry.
All patients underwent anamnestic and physical examination,
standard laboratory tests including the measurement of serum
tumor markers such as TK, B2m, LD, and CRP, as well as CT
scans of the chest, abdomen, and pelvis. In addition, unilateral
bone marrow aspiration and trephine biopsy were performed on
each patient. Pathological samples were reviewed by our expert
hematopathologists and classified according to the WHO/Revised
European-American Lymphoma classification of lymphoid neo-
plasm. An experienced physician selected the target tumor mass of
interest (the region containing the largest tumor or the greatest
number of .1 cm lymph nodes) for DWI analysis based on
clinical presentation and CT examination. Clinical prognostic
indexes, such as Ann Arbor stage and IPI/FLIPI were also
evaluated.
FDG-PET/CT image acquisition
All patients underwent an integrated PET/CT (Discovery STE
16, GE Healthcare, Milwaukee, WI, USA) examination. The
PET/CT imaging covered a volume from the skull base to the
upper thigh, and was acquired 72616 (Mean 6 SD) minutes after
intravenous injection of the 18F-FDG tracer (369622 MBq) under
fasting conditions (Patients were informed to fast at least 6 hours,
which was confirmed by an interview). The acquisition was in the
3-dimensional (3D) mode with a 1286128 matrix and 70 cm field
of view (FOV), 3 minutes per bed position. The PET images were
reconstructed using the 3D VUE Point reconstruction algorithm
(GE Healthcare) with 2 iterations and 28 subsets. The postfilter
used was 6.0 mm FWHM. The acquisition parameters of the CT
scanner were: tube voltage, 120 kV; tube current automatic
exposure control range, 100–440 mA; noise index, 18.5 HU;
rotation speed, 35 mm/rot; pitch, 1.75:1. The CT images were
reconstructed to slice thicknesses of 1.25 mm and 5.0 mm. The
total examination time for PET/CT was approximately 30 min-
utes.
PET/CT image analysis
The PET/CT images were evaluated visually and quantitative-
ly. The SUVmax, SUVmean, and MTV were measured from each
site (tumor or group of tumors). For each PET/CT dataset, the
tumor with the most intense 18F-FDG uptake among all foci was
carefully identified, and the SUVmax was measured on the fused
PET/CT images using the AW Volume ShareTM workstation (GE
Healthcare) [17].
For each tumor or group of tumors, the MTV was estimated in
a 3D manner by selecting volume of interest (VOI) on the axial
image, and the size of VOI was manually regulated on the
corresponding coronal and sagittal images to include the entire
active tumor in the VOI, and an isocontour threshold of 42% of
the SUVmax was determined between the background and the
maximal pixel value. The SUVmax, SUVmean, and MTV in the
VOI were computed automatically by the program [17].
MRI Protocol
MR imaging was acquired using a 3 Tesla MR System (Siemens
Trio-Tim, Erlangen, Germany) with the manufacturer’s body and
spine array coils. Additionally, a neck coil was used for the cervical
region examination. The MR imaging consisted of a whole-body
examination from the level of the skull base to the floor of the
pelvis in the coronal plane using a parallel acquisition technique.
High resolution axial images and DW images were acquired from
the target tumor/tumors. The MRI protocol included a coronal
PET/CT and DWI in Lymphoma
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T1-weighted turbo spin echo (TSE) imaging, a coronal T2-
weighted inversion-recovery imaging, an axial T1-weighted 3D
volumetric interpolated breath-hold examination (VIBE) with fat
suppression once before and once after gadolinium (Gd)-DOTA
(0.2 ml/kg DotaremH) injection, and an axial T2-weighted TSE
imaging once with and once without fat suppression. Before
contrast administration, DWI was acquired using a single-shot
echo-planar sequence with fat suppression in the axial plane with
two b values (0 and 800 s/mm2). The diffusion-weighting
gradients were applied in all three orthogonal directions. The
DWI was performed during normal respiration and the MR
parameters were different depending on the location of the target
tumor/tumors [18]. After acquisition of the DWI data sets, pixel-
by-pixel ADC maps were reconstructed automatically for each
patient.
ADC value measurement
The ADC value of the target tumor/tumors was measured
directly on the parametric ADC maps. A region of interest (ROI)
was manually placed on every slice of the entire tumor/tumors
that appeared as areas of low signal intensity. In order to ensure
proper positioning of the ROI on the ADC maps, the
corresponding T2-weighted images and contrast-enhanced T1-
weighted images were reviewed side-by-side. Any necrotic areas
were excluded from the analysis. For ADC measurement the
open-source software ImageJ (created by Wayne Rasband, freely
downloadable at the NIH website: http://rsb.info.nih.gov/ij/) was
used, which lists the intensity of each pixel within every ADC slice
in a single ROI output file. In this manner, the minimum and
mean ADC values were calculated. The ADCmin was defined as
the lowest ADC value within all of the slices of the target tumor/
tumors. Accordingly, the ADCmean was defined as the mean value
of all of the target tumor/tumors pixels in all of the slices.
Statistical analysis
The statistical analyses were performed using SPSS software.
Mann-Whitney U test was used to compare functional imaging
and serum markers between the DLBCL and FL groups. The
Spearman’s correlation coefficient was used to evaluate the
correlations between the ADCmin or ADCmean and SUVmax,
SUVsum, MTVwb, or MTBwb, as well as correlations between
imaging markers derived from PET/CT or DWI and stage, IPI
categories, or serum tumor markers. P values less than 0.05 were
considered significant. Receiver operating characteristic (ROC)
curve was used to determine the cut-off values of SUVmax, TK,
LD, and CRP with the use of the best combination of sensitivity
and specificity to differentiate between DLBCL and FL.
Results
Patient characteristics
Thirty-four pretherapy patients with DLBCL or FL (17 male
and 17 female; mean age, 63 years; range, 32 to 86 years)
underwent PET/CT and MRI examinations within two days.
Twenty-three patients had DLBCL including 3 patients with
concomitant DLBCL and FL, and 11 patients had FL: 10 with FL
grade II and one with FL grade III. The clinical characteristics of
the 34 study participants and their tumors are shown in Table 1.
The SUV and ADC value between DLBCL and FL groups
The SUVmax was significantly higher in the DLBCL group than
that of the FL group (p,0.01) (Table 2 and an example image
Figure 1). The only patient with FL grade III had a SUVmax of
30.2, which is much higher than the SUVmax of those with FL
grade II. Serum levels of TK, LD, and CRP were significantly
higher in the DLBCL group than in the FL group. However, there
was no significant difference in the ADCmin, ADCmean, or serum
B2m value between the two groups (Table 2).
To further investigate whether the SUVmax, serum LD, TK, or
CRP can differentiate DLBCL from FL, we used ROC curve
analysis (Figure 2). The area under the ROC curve (AUC) was
0.796, 0.763, 0.787, or 0.787; respectively, which suggested that
these markers were reasonable predictors for differentiating
diagnosis. The SUVmax cut-off value of $10.5 (normal value
,2.5) provided a fair balance, with sensitivity 87% and specificity
55% to detect a DLBCL. When a TK cut-off value of $10.5 (U/l)
(normal range 0–0.8 U/l) or a LD cut-off value of $200.5 (U/l)
(normal range 105–205 U/l) was used, yielded sensitivity 83% and
specificity 64% to detect a DLBCL. When a CRP cut-off value of
$1.85 (mg/l) (normal range 0–10 mg/l) was used, yielded
sensitivity 87% and specificity 64% to detect a DLBCL. A higher
cut-off value would capture more FLs. Conversely, a lower cut-off
value would capture a higher percentage of DLBCLs.
Correlations between SUV and ADC
The SUV evaluated from PET/CT and the ADC determined
from DWI were compared. The SUVmax correlated inversely with
the ADCmin (r =20.35, p,0.05) in all cases (Figure 3a). No
correlation was detected in the DLBCL or FL group when
Table 1. Demographic characteristics, tumor pathology, and
clinical staging of 34 patients with DLBCL or FL.
Characteristics DLBCL (n =23) FL (n =11) Total (n = 34)
Age (years)
mean 64 60 63
range 32–86 43–77 32–86
gender
female 9 8 17
male 14 3 17
Histology 23 DLBCL 10 FL II, 1 FL III 34
Ann Arbor stage
I 1 0 1
II 5 1 6
III 5 7 12
IV 12 3 15
IPI or FLIPI*
0–1 5 0 5
2 7 5 12
3 8 4 12
4 3 2 5
Target tumor site
abdomen 10 6 16
neck 8 1 9
upper thigh 3 1 4
thorax 2 1 3
pelvis 0 2 2
*IPI (International Prognostic Index) was used for the evaluation of DLBCL. IPI 1:
low risk; IPI 2: low-intermediate risk; IPI 3: high-intermediate risk; IPI 4: high risk.
* FLIPI (Follicular Lymphoma International Prognostic Index) was used for FL.
FLIPI 0–1: low risk; FLIPI 2: intermediate risk; FLIPI$3: high risk.
doi:10.1371/journal.pone.0084999.t001
PET/CT and DWI in Lymphoma
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subgroup analysis was performed. The SUVsum correlated
inversely with the ADCmean (r =20.42, p,0.05) in all cases
(Figure 3b). The inverse correlation was limited in the FL group
(r =20.73, p,0.05) when subgroup analysis was performed. No
correlation was found between the SUVmax and ADCmean or
SUVsum and ADCmin.
Correlations between ADCmin or ADCmean and MTVwb or
MTBwb
The ADCmin correlated inversely with MTVwb in all cases
(r =20.54, p,0.01) (Figure 4a). These values also correlated
inversely in the DLBCL (r =20.45, p,0.05) and FL group
(r =20.74, p,0.05); respectively. The ADCmin correlated in-
versely with MTBwb (r =20.47, p,0.01) in all cases (Figure 4b).
The inverse correlation was limited in the FL group (r =20.69,
p,0.05) when the analysis was performed in the subgroups.
The ADCmean correlated inversely with MTVwb in all cases
(r =20.43, p,0.05) (Figure 5a). The inverse correlation was
limited in the FL group (r =20.75, p,0.01) when the analysis was
performed in the subgroups. The ADCmean correlated inversely
with MTBwb in all cases (r =20.35, p,0.05) (Figure 5b). The
inverse correlation was limited in the FL group (r =20.65,
p,0.05) when subgroup analysis was performed.
Correlations between imaging markers and serum
markers
The data revealed good correlations between all the measured
serum tumor markers (i.e., TK, B2m, LD, and CRP) and MTVwb
or MTBwb regardless of disease types (p,0.01; respectively)
(Table 3). Subgroup analyses showed that TK, LD, or CRP
correlated with both MTVwb and MTBwb (p,0.01; respectively)
Figure 1. Diffusion-weighted MRI and PET/CT images showing
the abdominal region tumor in a 76- year old male patient with
diffuse large B-cell lymphoma. (a) B0 image. (b) Diffusion-weighted
image with b value 800 s/mm2 showed the hyperintensity tumor, but it
was not able to depict diffuse spleen involvement. (c) The correspond-
ing ADC map showed the hypointensity tumor with ADCmin
0.3461023 mm2/s and ADCmean 0.68610
23 mm2/s. (d) Axial CT image.
(e) FDG-PET image. (f) The fused PET/CT image showed the active tumor
and spleen involvement with SUVmax 23.9.
doi:10.1371/journal.pone.0084999.g001
Table 2. Comparison of PET/CT and DWI indexes and serum biomarkers in the DLBCL and FL groups.
DLBCL group (N=23) Median (Mean ±
SD) FL group (N=11) Median (Mean ± SD) P value*
SUVmax 23.9 (21.467.6) 10.2 (12.567.1) 0.004
SUVsum 45.7 (54.0634.9) 20.0 (48.6645.0) 0.291
MTVwb (ml) 146 (2816288) 83 (2676423) 0.490
MTBwb 1860 (368264364) 550 (165862215) 0.201
ADCmin (610
23 mm2/s) 0.40 (0.3860.11) 0.44 (0.4860.16) 0.091
ADCmean (610
23 mm2/s) 0.76 (0.7160.17) 0.78 (0.7660.12) 0.308
TK (U/l) 28.0 (83.06162.7) 9.9 (14.9613.7) 0.013
B2m (mg/l) 2.4 (2.860.9) 2.1 (2.461.0) 0.243
LD (U/l) 292 (4496445) 196 (199632.7) 0.007
CRP (mg/l) 10.5 (20.0625.7) 1.4 (13.6638.3) 0.007
*Comparison between the DLBCL and FL groups.
doi:10.1371/journal.pone.0084999.t002
Figure 2. Receiver operating characteristic curve analysis of
SUVmax, serum TK, LD, and CRP in 34 patients with DLBCL or
FL. The area under the ROC curve (AUC) was 0.796, 0.763, 0.787, or
0.787 for the SUVmax, serum TK, LD, or CRP; respectively. When the
SUVmax$10.5 was used as a cut-off value to differentiate DLBCL from FL,
yielded sensitivity 87% and specificity 55%. When a TK cut-off value of
$10.5 (U/l) or a LD cut-off value of $200.5 (U/l) was used to
differentiate DLBCL from FL, yielded sensitivity 83% and specificity 64%
to detect a DLBCL. When a CRP cut-off value of $1.85 (mg/l) was used
to differentiate DLBCL from FL, yielded sensitivity 87% and specificity
64% to detect a DLBCL.
doi:10.1371/journal.pone.0084999.g002
PET/CT and DWI in Lymphoma
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and B2m correlated with both MTVwb and MTBwb (p,0.05;
respectively) in the DLBCL group. TK or B2m correlated with
both MTVwb and MTBwb (p,0.05; respectively) in the FL group,
but no correlation was detected between LD or CRP and MTVwb
or MTBwb.
In addition, TK correlated inversely with ADCmin (r =20.35,
p,0.05), LD correlated with both ADCmin (r =20.48, p,0.01)
and SUVmax (r = 0.41, p,0.05), and CRP correlated with SUVmax
(r = 0.41, p,0.05) in all cases (Table 3). Subgroup analysis showed
that LD correlated inversely with ADCmin in the DLBCL cases
(r =20.48, p,0.05), and LD correlated with SUVmax in the FL
cases (r = 0.63, p,0.05).
Correlations between functional imaging markers, serum
markers, and IPI categories
There were moderate correlations between the IPI and MTBwb
(r = 0.41, p,0.05) or SUVsum (r = 0.42, p,0.05) in the DLBCL
group. No correlation was detected between the IPI and ADC
value. No correlation was detected between the FLIPI and
imaging biomarkers in the FL group. Serum B2m correlated with
IPI in the DLBCL group (p,0.05). Serum B2m, LD, or TK
correlated with Ann Arbor stage in all cases (p,0.05, respectively)
(Table 3).
Discussion
The IPI, a strong predictor of survival in aggressive NHL, was
determined from five factors: age, tumor stage, serum LD
concentration, performance status, and number of sites of
extranodal involvement. It has been used as the standard clinical
tool in the selection of appropriate treatment strategies for
individual patients. However, there are still significant differences
in outcomes within the same prognostic categories. Therefore,
more efficient prognostic markers or models to stratify patients
with different survival outcomes are needed. Imaging biomarkers
are important for detection and characterization of cancers as well
as for monitoring the response to therapy. Integrated PET/CT,
with the advantage of combining functional and anatomical
information and better attenuation correction, is regarded as
current standard reference for the management of lymphomas [3].
Several studies have demonstrated a relation between higher FDG
uptake and more aggressive course of malignancy in NHL [19,20].
High SUV is correlated with rapid cellular proliferation in
different subtypes of NHL [19,21–24].
Diffusion-weighted MRI is based on a different approach. In
DWI, the random thermal motion of free water molecules known
as the Brownian motion can be visualized in vivo, and the ADC
value varies according to the microstructure and pathophysiolog-
ical state of the tissues. Within biological tissue, unrestricted free
diffusion of molecules does not exist due to cell membranes,
Figure 3. Scatter plots showing the correlations between the SUVmax and ADCmin, (a), and between the SUVsum and ADCmean (b) in
34 patients with DLBCL or FL. The SUVmax correlated inversely with the ADCmin (r =20.35, p,0.05) (Figure 3a), and the SUVsum correlated
inversely with the ADCmean (r =20.42, p,0.05) (Figure 3b) in all cases.
doi:10.1371/journal.pone.0084999.g003
Figure 4. Scatter plots showing the correlations between the ADCmin and the MTVwb or MTBwb in 34 patients with DLBCL or FL. The
ADCmin correlated inversely with the MTVwb (r =20.54, p,0.01) (Figure 4a), and it also correlated inversely with the MTBwb (r =20.47, p,0.01)
(Figure 4b) in all cases.
doi:10.1371/journal.pone.0084999.g004
PET/CT and DWI in Lymphoma
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organelles and molecular boundaries. In malignant tissue, the
microstructural environment that has increased cellularity and
dense tumor cell membranes, larger cell nuclei and more
abundant macromolecular proteins as well as reduced extracellu-
lar space is known to act as a diffusion barrier leading to a decrease
of water mobility. On the other hand, necrosis and apoptotic
processes may lead to a decrease of cellularity and loss of cell
membrane integrity. This, in turn, increases the amount of free
water diffusion across the cell membrane and in the extracellular
space [6,8,15].
In this study, we evaluated the SUV and ADC in patients with
DLBCL and FL, and detected an inverse correlation between the
SUVmax and ADCmin. This is in agreement with a recent study in
Hodgkin’s lymphoma (HL) [25]. In addition, several investigators
have reported a significant inverse correlation between SUVmax
and ADCmin in various tumors including rectal cancer [13], lung
cancer [12], gastrointestinal stromal tumor [14], cervical cancer
[15], and endometrial cancer [16]. However, there were also
contradictory results. For example, an inverse correlation between
the ratio of ADCmin/ADCmean and SUVmax/SUVmean was
reported in 33 patients with uterine cervical cancer, but neither
ADCmin nor ADCmean correlated with SUVmax or SUVmean [26].
The possible explanation for this finding is that different
pathological types of cervical cancer patients including squamous
cell carcinoma, adenocarcinoma, and adenosquamous carcinoma
were present in the study cohort. In our study, there was a better
correlation between the PET/CT and DWI derived markers in
the FL group compared with the DLBCL group. This could be
explained by the fact that the FL group was relatively homogenous
in pathology; all 11 patients had FL grade II, except for one with
FL grade III. In contrast, the DLBCL group had obvious
pathological variability, including varying differentiating levels of
DLBCL and concomitant DLBCL and FL cases. Cancer grows
not only with a high proliferation rate, resulting in abnormally
high number of cells, but also with architectural alterations in
tumor cells and tissue. Changes in nuclear structure are among the
most universal of these, a larger cell nuclear size usually means a
more aggressive tumor [5]. The decreased ADC value in
malignant tumors may be a result of their increased cellularity,
larger nuclei with more abundant macromolecular proteins
(aggressiveness), and decreased extracellular space. Thus, the
ADC value correlates with tumor aggressiveness in specific tumor
histological subtype [27]. In contrast, the SUVmax reflects the
highest tumor metabolic rate, regardless of the underling
microstructure changes. Thus, the SUVmax and ADCmin are
independent functional imaging markers that may complement
each other in the management of lymphomas, and to use both
types of data may improve the accuracy of diagnoses [15].
The SUVsum reflects the total tumor metabolic activity of the
whole body and the ADCmean indicates the overall tumor
cellularity and aggressiveness. It is not surprising that an inverse
correlation between the SUVsum and ADCmean was also detected
in this study. To our knowledge, this is the first report of the
relation between SUVsum and ADCmean, and this finding needs to
be verified in future studies. In addition, both the ADCmin and the
ADCmean correlated inversely with MTVwb and MTBwb, which
reflect the total metabolic tumor volume or total amount of tumor
glycolysis in the patient’s body. These correlations could be
explained by the fact that a lower ADC value indicates increased
aggressiveness. In general, more aggressive tumors proliferate
more rapidly and with a higher risk of metastasis, and accordingly
the MTVwb and MTBwb are also greater. No correlation was
detected between SUVmax and ADCmean. This is in agreement
with our previous lesion-wise comparison of SUVmax and
ADCmean in DLBCL [10], since the SUVmax represents the most
malignant site of the heterogeneous tumors, whereas ADCmean
indicates the overall tumor aggressiveness.
Both DLBCL and FL had a wide range of FDG avidity. Our
result showed that SUVmax was a useful marker in differentiating
Figure 5. Scatter plots showing the correlations between the ADCmean and the MTVwb or MTBwb in 34 patients with DLBCL or FL. The
ADCmean correlated inversely the MTVwb (r =20.43, p,0.05) (Figure 5a), and it also correlated inversely with the MTBwb (r =20.35, p,0.05) (Figure 5b)
in all cases.
doi:10.1371/journal.pone.0084999.g005
Table 3. Correlations (Spearman’s rho) between clinical
stage, IPI, or functional imaging markers and serum markers in
34 patients with DLBCL or FL.
TK (U/l) B2m (mg/l) LD (U/l) CRP (mg/l)
MTVwb (ml) r = 0.63 ** r = 0.53 ** r = 0.66 ** r = 0.58 **
MTBwb r = 0.57 ** r = 0.56 ** r = 0.67 ** r = 0.58 **
SUVmax r = 0.31 r = 0.25 r = 0.41 * r = 0.41 *
ADCmin (610
23
mm2/s)
r =20.35 * r =20.06. r =20.48 * r =20.27
Ann Arbor Stage r = 0.60 ** r = 0.41 * r = 0.44 * r = 0.26
IPI or FLIPI r = 0.28 r = 0.38 * r = 0.37 * r = 0.34
*p,0.05 and
**p,0.01.
doi:10.1371/journal.pone.0084999.t003
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between DLBCL and FL, although overlap between the two types
of disease existed. A SUVmax cut-off value of $10.5 was indicative
of aggressive disease. The only patient with FL grade III had much
higher SUVmax compared with those with FL grade II. This is in
agreement with previous studies showing that indolent FL is
associated with low-grade FDG uptake, and more intense FDG
accumulation has been observed in more aggressive B-cell
lymphomas [19,20]. Although typically biopsies are obtained
from areas that are easily accessible, an unexpectedly high
SUVmax may suggest a transformation of an indolent NHL to a
more aggressive disease and a new biopsy of the site with the
highest SUVmax should be considered. Therefore, our results
suggest that PET scanning may also be helpful in directing biopsies
and changing clinical management. In contrast, DWI with ADC
value measurement is inferior to PET/CT derived SUVmax in
differentiating DLBCL from FL and is therefore not able to guide
biopsy. This finding is concordant with a previous study in a group
of 16 indolent and 16 aggressive NHL patients [28]. The possible
explanation is that ADC value reflects both tissue cellularity and
tumor aggressiveness, but aggressive tumors do not always have
higher cellularities. e.g., we have demonstrated that FL had a
higher cellularity than DLBCL [17]. Thus far, the most promising
oncologic application of DWI seems to be in tumor detection and
treatment response evaluation [6].
In our study, serum TK, LD, and CRP were significantly higher
in the DLBCL group than in the FL group. ROC analysis showed
that they are useful markers in differentiating the two common
types of indolent and aggressive lymphoma. Serum LD represents
a surrogate quantitative measure of tumor burden and aggres-
siveness in NHL [29], and it is a one of the components of the IPI.
A high serum B2m level is an independent adverse prognostic
factor in malignant lymphoma, which is also related to the tumor
burden [30,31]. CRP is an acute-phase reactant, and elevated
baseline serum CRP levels have also been found to be a poor
prognostic factor in cancers of many types [32,33]. High serum
CRP might reflect a high metastatic potential, as it is known to
promote metastatic spread by stimulating angiogenesis, increasing
vascular permeability, and acting as an endothelial cell mitogen
[34]. Elevated serum TK predicts high proliferation of tumor cells
in lymphoma [35]. Our study showed that serum LD, TK, CRP
or B2m correlated with both MTVwb and MTBwb. Therefore,
these serum tumor markers could serve as clinically useful markers
in malignant NHL, since they are widely available and relatively
inexpensive. In addition, a recent study showed that they are
independent prognostic markers [36]. The IPI correlated with
quantitative PET/CT functional markers (MTBwb and SUVsum)
in the DLBCL group. This indicates that the IPI remains a useful
and simple clinical tool in evaluating the risk and prognosis of
aggressive NHL.
There was a limitation in our study, the PET/CT was a whole
body examination, but the DWI was performed only in the target
tumor/tumors. As such, ADCmin might not be the minimum ADC
of the whole body, since the largest tumor was not always the one
with the highest malignancy. Additionally, the study included only
a small cohort, and future studies with larger patient cohorts are
needed to confirm our findings.
Conclusions
Glucose metabolism with PET/CT and ADC value with DW-
MRI are different indexes for the characterization of lymphomas.
The functional imaging markers derived from DWI and FDG-
PET/CT are associated, and FDG-PET/CT is superior to DWI
in differentiating DLBCL from FL. The measured serum tumor
markers such as LD, TK, CRP, and B2m are associated with
functional imaging markers, and LD, TK, and CRP are useful in
differentiating DLBCL from FL.
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